Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Eur Acad Dermatol Venereol ; 31(8): 1260-1270, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28252812

RESUMO

New all-oral direct-acting antivirals (DAA) have changed the hepatitis C virus (HCV) treatment landscape. Given that dermatologists frequently encounter HCV-infected patients, knowledge of the current treatment options and their utility in treating HCV-associated dermatologic disorders is important. In addition to highlighting the new treatment options, we review four classically HCV-associated dermatologic disorders - mixed cryoglobulinaemia (MC), lichen planus (LP), porphyria cutanea tarda (PCT) and necrolytic acral erythema (NAE) - and examine the role for all-oral direct-acting antiviral (DAA) regimens in their treatment. A literature search of English-language publications was conducted of the PubMed and EMBASE databases using search terms including 'hepatitis C', 'direct acting antivirals', 'cutaneous', 'mixed cryoglobulinemia', 'necrolytic acral erythema', 'lichen planus', 'porphyria cutanea tarda', 'rash', as well as specific drug names, related terms and abbreviations. Currently, limited data exist on the use of DAAs in HCV-infected patients with cutaneous side-effects, although treatment of the underlying HCV is now recommended for nearly all patients, with the new drugs offering much-improved dosage schedules and side-effect profiles. The most data exist for MC, in which several studies suggest that DAAs and achievement of sustained virologic response (SVR) improve cutaneous symptoms. Studies of both older and newer regimens are limited by their small size, retrospective nature, lack of appropriate controls and wide variability in study protocols. Given the strong association, screening for HCV should be considered in patients with MC, LP, PCT and NAE.


Assuntos
Antivirais/uso terapêutico , Crioglobulinemia/virologia , Eritema/virologia , Hepacivirus/patogenicidade , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Líquen Plano/virologia , Porfiria Cutânea Tardia/virologia , Humanos
2.
J Otolaryngol ; 21(3): 209-12, 1992 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1404573

RESUMO

It has been proposed that head-shaking nystagmus is a reliable test or indicator of vestibular dysfunction. Using a series of 340 patients and 20 controls, this paper compares the vestibular test data to head-shake test data to answer some of the questions about this poorly understood response. Head-shaking nystagmus appears to reflect the underlying spontaneous nystagmus and its direction has no relationship to the side of the vestibular asymmetry.


Assuntos
Eletronistagmografia/métodos , Doenças do Labirinto/diagnóstico , Nistagmo Fisiológico , Testes Calóricos , Feminino , Humanos , Doenças do Labirinto/fisiopatologia , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...